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APC	 	antigen presenting cells
CD4		ISQAVHAAHAEINEAGR peptide 
CD8		SIINFEKL peptide 
CPP		cell penetrating peptide 	
CPRG		chlorophenolred--galactoside 
CTL		cytotoxic T lymphocytes 
DC		dendritic cells 
Antp		penetratin 16-mer peptide - RQIKIWFQNRRMKWKK 
AntpCD4	Antp tandemly linked to ISQAVHAAHAEINEAGR peptide 
AntpCD8	Antp tandemly linked to SIINFEKL peptide 
AntpCD8-4	Antp tandemly linked to CD8 and CD4 peptides 
AntpOVA	Antp covalently liked to ovalbumin
OVA		ovalbumin 
PEP	16mer peptide incorporating the malaria circumsporozoite protein H-2Kd (CSP245-253) T cell epitope
PEPOVA	16mer peptide incorporating the malaria circumsporozoite protein H-2Kd (CSP245-253) T cell epitope linked to ovalbumin







Peptide-based vaccines for cancer immunotherapy using defined CD8+ T cell epitopes from tumor antigens have been utilized in many clinical trials for a number of different cancers, particularly melanoma  ADDIN EN.CITE (1-8). Although the use of peptides in immunotherapy has provided promising results in clinical studies, there are limitations to this therapy. The delivery of immunogenic tumor antigens requires pulsing dendritic cells (DCs) ex-vivo for the induction of cytotoxic T lymphocyte (CTL) responses. This process is labor intensive and expensive and requires multiple immunizations for the patient. Although peptide-based vaccines can induce remarkable CTL responses, poor clinical responses have been observed since many cancers downregulate MHC class molecules on their surface and CTL induction may be ineffective (9,10). Thus, it may be more advantageous to use intact proteins or peptides that incorporate both CD4+ and CD8+ epitopes in peptide-based vaccines to induce CD4+ mediated immune responses (11,12). Peptide or protein-based vaccines without a mechanism of delivery into antigen-presenting cells have limited uptake. To overcome this problem, methods such as targeting cell surface receptors or the use of cell penetrating peptides to deliver proteins into the cytoplasm of cells have been investigated (6). 

A 16 amino acid peptide from the homeo domain of the Antennapedia transcription factor of Drosophila ranging from amino acid 43-58 (Antp; penetratin; RQIKIWFQNRRMKWKK) has been used for delivery of antigenic peptides into the cytosol of cells for efficient processing and presentation via the MHC class I pathway and induction of CTLs in vivo without the use of ex-vivo pulsed DCs (13). In addition, studies have shown that intradermal and epicutaneous delivery of penetratin linked to the CD8+ T cell epitope of ovalbumin, SIINFEKL (CD8), induce anti-tumor immunity in mice in vivo (14,15). Similarly, a recombinant fusion protein consisting of the 60 amino acid homeodomain fused to an influenza nucleoprotein derived CTL peptide generated CTLs to the peptide, however SDS was required to denature the antigen (13).

We have recently shown that penetratin conjugated to MUC1 proteins and H-2Kb or HLA-A2 restricted CTL epitopes induced IFN-secreting T cells and weak IgG1 antibodies in mice and were protective against the growth of a MUC1+ tumor cell line (16). In addition we demonstrated that penetratin tandemly linked to the CTL peptide of ovalbumin, SIINFEKL (AntpCD8), is endocytozed by DCs via phagocytosis or macropinocytosis in an ATP-dependent manner and is processed by a proteasome and tapasin (TAP) independent pathway for loading onto MHC class I molecules. Further, the majority of antigen is taken up by negatively charged receptors (17). 














































CD8 [SIINFEKL] is the ovalbumin H-2Kb CTL epitope 8-mer peptide (18). OVA323-339 is the ovalbumin I-Ab CD4 epitope 16-mer peptide, [CD4] (ISQAVHAAHAEINEAGR). Penetratin (Antp) is the 16 amino acid Antennapedia peptide (RQIKIWFQNRRMKWKK). The 16mer control peptide (CKKKAAASYIPSAEKI) incorporating the malaria circumsporozoite H-2Kd (CSP245-253) T cell epitope (Table 1) and all peptides were synthesized by GenScript Corporation (USA). The purity of the peptides (>95%) was determined by mass spectrometry. Ovalbumin protein (OVA) was purchased from Sigma (VIC, Australia) and treated with Triton X114 to remove endotoxin (19).

Conjugation of penetratin to ovalbumin






Bone marrow cells from female C57BL/6 mice were cultured at 106 cells/ml in petri dishes containing 10ml of complete medium [RPMI-1640 medium supplemented with 10% (v/v) heat inactivated foetal calf serum (FCS), 4mM L-glutamine, 100units/ml penicillin, 100 g/ml streptomycin sulphate and 100 M -mercaptoethanol (CSL, Australia)] with 10 ng/ml of GM-CSF and 10 ng/ml of IL-4. At day 6, cells cultured under these conditions expressed medium-high levels of CD11c, CD40, CD80 and CD86, characteristic of semi-mature DCs and were approximately 80% CD11c+ and MHC class II+ (not shown). DCs were flushed from each dish and washed then were used to assess the kinetics of uptake of Antp-conjugates by flow cytometry and for pulsing. 


Kinetics of AntpOVA uptake

C57BL/6 DCs (0.5x106cells in 1ml complete medium) were used. Uptake kinetics were assessed by adding AntpOVA and OVA for various times (5-120 min) at a fixed concentration (2.3 M) or for a fixed time (60 min) at varying concentrations (0.4 – 4 M). Uptake of antigen was assessed by flow cytometry and % fluorescent live cells were measured. After incubation, the cells were washed twice with 0.5% BSA/PBS, fixed with 2% paraformaldehyde (10 min) and washed again with 0.5% BSA/PBS. The cells were then permeabilized with 0.5% Saponin/PBS for 10 min and anti-OVA polyclonal antibody (1:10,000 diluted in saponin/PBS) was added for 45 min at 4°C. After washing the cells with Saponin/PBS 1:50 anti-F(ab`)2-FITC in Saponin/PBS was added for a further 45 min at 4°C. Finally cells were washed twice with 0.5% BSA/PBS. Cells were resuspended in PBS and transferred into FACS tubes and analyzed using a flow cytometer (FACSCalibar, BD Biosciences).

Stimulation of lacZ inducible ovalbumin-specific T cell hybrid

The B3Z T cell hybridoma line contains a gene construct of E.coli lacZ reporter gene linked to the nuclear factor of activated T cells (NFAT). Recognition of H-2Kb restricted peptide from OVA (SIINFEKL) [CD8] by the TCR results in activation of the enzyme and conversion of the chromogenic substrate that can be measured by absorbance spectrophotometry (20). 106 C57BL/6 DCs were pulsed with different doses of AntpOVA (0.4 - 4 M), OVA (0.47 - 4.8 M), AntpCD8-4 (0.3 - 2.4 M), AntpCD4 (0.3 - 2.4 M) or AntpCD8 (0.3 - 2.4 M) for 24 h. The peptide preparations used were equivalent in molar concentrations. 2x105 DCs were added to 105 B3Z T cells in 96 well microtitre plates. After overnight incubation at 37oC, cells were washed with sterile PBS and incubated with chloro phenolred galactoside (Calbiochem, San Diego, CA) for a further 4 h and absorbance was measured at 560 nm using a microplate reader.

Antigen-specific OT-I and OT-II T cell responses in vitro





C57BL/6 mice were purchased from the Animal Facility at WEHI, Parkville Australia. To determine effector immune responses induced by the Antp conjugates, C57BL/6 mice were immunized intradermally on days 0 and 14 with AntpOVA, AntpCD8-4, AntpCD8, AntpCD4 or AntpCD4+AntpCD8 and immune responses assessed 16 days later. To determine long-term immune responses induced by the Antp conjugates, C57BL/6 mice were immunized intradermally on days 0 and 14 with AntpOVA, AntpCD8-4, AntpCD8 and AntpCD4 and immune responses assessed 40 days later. In these experiments one experimental group were immunized with AntpCD8 on day 0 and then again with AntpCD4, 7 days before immune responses and tumor challenges were assessed at day 40. Mice in different groups received equimolar amounts of CD4 and CD8 peptide at 7.8 mole. 


Antigen-specific T cell responses in vivo





Prophylactic tumor protection experiments: Groups of immunized C57BL/6 mice were challenged subcutaneously with 106 B16.OVA cells. B16.OVA cells (B16 tumor cell line (C57BL/6 derived, H-2b)) transfected with OVA cDNA and were cultured in 10% (v/v) FCS/RPMI 1640 media. The expression of OVA on B16.OVA tumor cells prior to challenge was confirmed by flow cytometry (not shown). 
Treatment of established tumors: C57BL/6 mice were injected subcutaneously with 2x105 B16.OVA cells. 4 days later, mice were immunized once with PEPOVA or AntpOVA at 25 g per mouse, intradermally. 











Internalization of Antp by DCs

To analyze the kinetics of Antp uptake, in vitro grown DCs were incubated with AntpOVA and OVA alone (100g/ml) for various times (Fig. 1A). Uptake of AntpOVA was noted rapidly within 5 min (>40%) and was sustained at the same level for 120 min; by comparison uptake of OVA reached a maximum of 10-15%. Thus, the presence of ‘Antp’ conferred rapid uptake and a higher % of positive cells compared to the same protein without Antp (Fig. 1A). When the uptake of different doses of AntpOVA was compared to that of OVA, DCs pulsed with OVA showed minimal uptake (up to 5%), whereas that of AntpOVA was significantly higher at all concentrations [4 M (47%), 2 M (39%), 1 M (27%) and 0.4 M (17%)] (Fig. 1B). To verify the role of Antp in antigen internalization, an irrelevant 16-mer peptide from the Plasmodium berghei CS protein (PEPOVA) was conjugated to OVA and uptake by DCs assessed by flow cytometry (Fig. 1C). AntpOVA showed consistent uptake by DCs over a range of concentrations compared to PEPOVA which did not show any significant uptake (Fig. 1C).

Recent studies have shown that apparent ATP and temperature independence and fast kinetic uptake of cell-penetrating peptides results from artifacts of cell fixation and incomplete removal of surface-bound peptide (21). However, we recently demonstrated that uptake of AntpMUC1 peptides and AntpMUC1FP proteins by DCs occurs via endocytosis and that intracellular fluorescence/uptake is not due to the artifacts of the fixation process (16).


Presentation of the CD8 T cell epitope from AntpOVA and AntpCD8-4 by MHC class I and stimulation of B3Z T cells in vitro

To assess whether AntpOVA and AntpCD8-4 are processed and presented by DCs to the TCR of B3Z T cells (T cell hybridoma which recognizes OVA CD8 epitope), DCs were pulsed with AntpCD8-4, OVA or AntpOVA at 4, 2, 1 and 0.4 M for 24 h at 37oC. These molar concentrations overlapped and were equivalent to 1 g/ml of AntpCD8 (used as the positive control). Pulsed DCs were incubated with B3Z T cells for 24 h and recognition of the peptide loaded MHC class I molecules was assessed via a colorimetric assay. DCs alone were used as a negative control. DCs pulsed with AntpOVA (0.4 - 4 M) showed an increase in absorbance compared to non-pulsed DCs and was significantly higher than DCs pulsed with OVA alone (Fig. 2A). Similarly, DCs pulsed with AntpCD8-4 (0.6 - 2.4 M) presented better than non-pulsed DCs and DCs pulsed with AntpCD4 but not as efficiently as AntpCD8 at similar molar concentrations (Fig. 2B). The results observed with DCs pulsed with AntpCD8 presenting to B3Z T cells were similar to those previously published  where we were able to show more efficient presentation than DCs pulsed with a non-internalizing 24-mer peptide (Fig. 2) (14,17). These results clearly indicate that DCs pulsed with AntpOVA, AntpCD8-4 and AntpCD8 can present CD8 epitopes on MHC class I molecules to antigen-specific T cells.


AntpOVA, AntpCD8, AntpCD4 and AntpCD8-4, stimulate antigen-specific CD8+ and/or CD4+ T cell responses in vitro

To determine the ability of AntpOVA, AntpCD8, AntpCD4 and AntpCD8-4 presenting via MHC class I or II pathways, transgenic OT-I (CD8+ MHC class I-restricted) and OT-II (CD4+ MHC class II-restricted) purified T cells were used. DCs were pulsed with AntpOVA, OVA proteins and AntpCD8, CD8, AntpCD4, CD4 and AntpCD8-4 peptides for 24 h at 37oC and added to purified OT-I or OT-II T cells at a ratio of 1:10. Co-cultured cells were left for 6 days and each day, proliferation was assessed via incorporation of [3H]-thymidine. The CD8 peptide is surface loaded and does not require antigen processing and was therefore used as a positive control (Fig. 3A). AntpCD8 stimulated OT-I T cells efficiently as previously demonstrated (Fig. 3A) (14,17). DCs pulsed with AntpOVA demonstrated efficient processing and presentation of MHC class I to OT-I T cells and peak proliferation was observed between days 2-3, with responses returning to background by day 4 (Fig. 3B). DCs pulsed with AntpCD8-4 stimulated OT-I T cells as did DCs pulsed with the CD8 peptide, peaking at day 3 (Fig. 3C). Non-pulsed DCs (DC+T) and DCs pulsed with the CD4 peptide or AntpCD4 did not show any stimulation of OT-I T cells and were used as additional negative controls (Fig. 3A-C). 

DCs pulsed with AntpOVA increased presentation of MHC class II peptide to OT-II T cells compared to DCs pulsed with OVA alone or PEPOVA, which failed to present to OT-II T cells and responses peaked between days 2-3 and returned to background levels by day 6 (Fig. 3E). DCs pulsed with AntpCD4 also stimulated OT-II T cells and peaked at day 4 (Fig. 3F); CD4 peptide was used as a positive control and stimulated OT-II T cells significantly better than AntpCD4 (Fig. 3F). DCs pulsed with AntpCD8-4 also induced significant proliferation of OT-II T cells and displayed similar kinetics to AntpCD4 with responses peaking between days 3-5 (Fig. 3F). Non-pulsed DCs (DC+T) and DCs pulsed with AntpCD8 or CD8 peptide did not show any presentation to OT-II T cells and were used as additional negative controls (Fig. 3D).

AntpOVA, AntpCD8, AntpCD4 and AntpCD8-4 induce potent CD8+ and/or CD4+ T cell specific IFN- responses in vivo

We have shown that DCs pulsed with AntpOVA, AntpCD8, AntpCD4 and AntpCD8-4 can present via MHC class I or II and stimulate CD8+ and CD4+ T cell responses in vitro which are facilitated by the presence of the Antp peptide. We further evaluated the potential of AntpOVA, AntpCD8, AntpCD4 and AntpCD8-4 conjugates to induce CD8+ and CD4+ T cell responses in vivo. C57BL/6 mice were immunized with PBS (negative control), AntpOVA, AntpCD8-4, AntpCD4 mixed with AntpCD8, AntpCD4 and AntpCD8. All mice were given two intradermal immunizations, 14 days apart and 16 days after the second immunization, spleens were removed and antigen-specific IFN- responses were detected by ELISpot assay (Fig. 4). Control immunized mice showed low background levels after re-stimulation with CD8, CD4 peptides and OVA protein (Fig. 4A). Mice immunized with AntpOVA (Fig. 4B), AntpCD8-4 (Fig. 4C) and AntpCD8+AntpCD4 (Fig. 4D) induced significant IFN- responses to CD8 and CD4 peptides and little response to OVA protein. The IFN-responses (SFU/5x105 cells) were similar in mice immunized with AntpCD8-4 and AntpOVA, however mice immunized with the mixture of AntpCD8+AntpCD4 generated higher numbers of IFN- secreting T cells/0.5x106 cells. This may indicate that the processing and presentation of AntpCD8+AntpCD4 may be more efficient in vivo compared to AntpOVA and AntpCD8-4; but it is important to note that all conjugates were able to induce statistically significant immune responses above controls. In addition, AntpCD4 (Fig. 4E) and AntpCD8 (Fig. 4F) immunizations generated specific IFN- responding CD4+ or CD8+ T cells, respectively. Mice immunized with DC alone or Antp alone did not induce T cell responses and were similar to background (no antigen) levels (data not shown). Also in previous ELISPOT experiments, we had tested the reactivity of the penetratin peptide alone on splenocytes from mice immunized with AntpOVA and AntpCD8 and showed no significant IFN- responses suggesting no cognate CD4 epitopes present within the AntpCD8 conjugate.

Mice immunized with DCs pulsed with Antp-conjugates induced similar CD8+ and CD4+ T cell responses to those generated with direct injection (Fig. 4) as has been shown in previously published studies (22). Studies on the mechanism of cellular uptake and presentation by class I and class II molecules demonstrate that Antp-conjugates are taken up by endocytosis (17). Therefore, Antp linked to peptides or proteins is comparable to ex-vivo pulsed DC immunization regimes for inducing cellular responses. This also presents the possibility of improving Antp-conjugate induced immunity in the presence of characterized adjuvants such as CpG and these studies are ongoing. 


Tumor protection against B16.OVA

Due to the potent in vivo immune responses elicited by AntpOVA, AntpCD8, AntpCD4, AntpCD8-4 and AntpCD4+AntpCD8, the anti-tumor effects of the Antp-conjugates were tested. Immunized C57BL/6 mice (n=6/group) were challenged subcutaneously with 106 OVA expressing B16 tumor cells (B16.OVA), 7 days after the second immunization. Growth of tumors in control mice (Fig. 5A) and mice immunized with AntpCD4 (Fig. 5E) was rapid and all mice grew tumors within the first 7 days of challenge and were sacrificed by day 11. 2/6 mice immunized with AntpOVA grew tumors up to a maximum of 100mm2 by day 11 (Fig. 5B). Mice immunized with AntpCD8-4 (Fig. 5C), AntpCD8+AntpCD4 (Fig. 5D) and AntpCD8 (Fig. 5F) showed significantly delayed tumor growth compared to control mice. After day 11, tumor growth was rapid in all experimental groups and there was no significant difference in tumor growth until day 17 when all mice were sacrificed for ethical reasons (not shown). Tumors from two mice immunized with AntpCD8-4 (Fig. 5C) and AntpCD8+AntpCD4 (Fig. 5D) were tested for OVA expression 15 days after tumor challenge and showed more than 70% loss of OVA expression (not shown) potentially explaining the rapid tumor growth observed in all groups after day 11. However, it was clear that until day 11, AntpOVA, AntpCD8-4, AntpCD8+AntpCD4 and AntpCD8 induced suppression of B16.OVA expressing tumor growth. Kaplan Meier survival curves showed that AntpOVA, AntpCD8-4, AntpCD8+AntpCD4 and AntpCD8 induced significant survival compared to both PBS and AntpCD4 immunized mice by day 11 (Fig. 5G). There were no significant differences in survival rates between mice immunized with AntpOVA, AntpCD8-4, AntpCD8+AntpCD4 or AntpCD8 (Fig. 5G).


CD4+ T cell help is important for induction of antigen-specific tumor immunity

There has been much discussion in the literature regarding the use of CD4 helper epitopes in peptide-based cancer vaccines and their effectiveness at inducing and maintaining antigen-specific memory CD8+ T cells. We observed that (16 days after boost immunization using AntpCD4 in combination with AntpCD8) did not improve the number of IFN- secreting CD8+ T cells compared to AntpCD8 alone nor improved B16.OVA induced tumor protection after 7 days. We therefore boosted immunized mice with AntpOVA, AntpCD8-4, AntpCD8+AntpCD4, AntpCD4 and AntpCD8 and compared in vivo antigen-specific IFN- responses 40 days later. Mice immunized with AntpCD4 showed significant IFN- responses to OVA and CD4 but not CD8 peptides (Fig. 6E). Immunization with AntpOVA showed significant IFN- responses to CD8 peptide (p<0.05), CD4 peptide (p<0.05) and OVA protein (p<0.05) (Fig. 6B). Immunization with the tandem conjugate, AntpCD8-4 induced significant IFN- responses to CD8 peptide (p<0.001), CD4 peptide (p<0.05) and OVA protein (p<0.001) (Fig. 6C). Immunization with the mixture of AntpCD8 and AntpCD4 induced a higher number of IFN- secreting spot forming cells compared to CD8 peptide (p<0.001), CD4 peptide (p<0.001) and OVA protein (p<0.001), 40 days after immunization compared to controls (Fig. 6D). AntpCD4 induced IFN- secreting cells only to the CD4 peptide (Fig. 6E) (p<0.05) whereas AntpCD8 immunization only induced IFN- responses to the CD8 peptide (Fig. 6F) (p<0.001). Interestingly, groups immunized with AntpCD8-4 and AntpCD8+AntpCD4 were the only ones in which significantly higher IFN- secreting numbers to CD8 peptide stimulation compared to AntpCD8 immunization were induced (Fig. 6). AntpOVA immunization did not induce higher IFN- secreting cells to CD8 peptide, CD4 peptide or OVA protein stimulation compared to AntpCD8 immunization (Fig. 6). 
 
Subsequent tumor challenge 40 days after a boost immunization showed that mice immunized with AntpCD8 delayed B16.OVA tumor growth compared to control mice (Fig. 7B). After day 10, tumors were less than 100mm2 and two mice remained tumor free, however by day 21, 75% of mice had to be culled due to their large tumor sizes (p<0.001). Mice immunized once with AntpCD8 and boosted with AntpCD4 7 days before tumor challenge showed delay in tumor growth and at day 10 all tumors were less than 100mm2 and two mice remained tumor free (Fig. 7C). However post-day 18, the majority of mice were still alive compared to only 25% of mice surviving in the AntpCD8 immunized group (p<0.05). Although the survival curve was not significantly better than AntpCD8 immunization, it did suggest that co-immunization with CD4 helper peptides could enhance immunotherapy efficiency of CTL based peptide immunizations. In addition, mice given two immunizations with the tandem peptide AntpCD8-4 showed a delay in tumor growth until day 10 post-challenge at day 14 all tumors were less than 100mm2, one mouse remained tumor free throughout the challenge time course and all mice survived until day 20 (Fig. 7D, p<0.001). The most significant delay in tumor growth was in mice immunized with both AntpCD8 and AntpCD4 where there was no visible tumor growth in any mice by day 11, all tumors were less than 100mm2 at day 15, all mice survived until day 23 and two mice remained tumor free throughout the time course (Fig. 7E, p<0.001). These mice were the only group that showed significantly better survival rates than mice immunized with AntpCD8 (p<0.001). Interestingly, mice immunized with AntpCD8-4 and AntpCD8+AntpCD4 showed rapid tumor growth after day 18 and analysis of the tumors showed loss of OVA expression by B3Z.IG7 assay (data not shown). These long-term experiments suggest that the use of CD4 peptides in peptide-based cancer vaccines enhances tumor-specific memory CD8 T cell responses and consequently generates more significant tumor delay in immunized mice.

Immunization with Antp conjugates induced therapeutic anti-tumor immunity 












Efficient generation of antigen-specific CTLs which recognize endogenously generated peptides presented by cell surface class I molecules is crucial for the destruction of tumor cells. As well, it has been shown that inclusion of MHC class II-restricted epitopes into CTL peptide-based vaccines is important at the priming stage for the generation of functional and long-lived memory CTLs (mCTLs) (23,24). Cell-penetrating peptides have the unique ability to internalize into live cells and potentially access both MHC class I and II pathways for generation of both CTL and Th cell responses (25). Therefore, these peptides offer many advantages for use in cancer immunotherapy. In the present study, we chemically linked penetratin to OVA (AntpOVA) for the purpose of evaluating both CTL and Th cell responses in vivo. In addition, penetratin linked in tandem to CD8 and CD4 T cell epitopes from OVA (AntpCD8-4) was investigated for the first time. In vitro and in vivo responses in mice were compared with penetratin linked to CD8 and CD4 T cell epitopes (AntpCD8, AntpCD4, AntpCD8+AntpCD4) as well as a multi-epitope conjugate containing penetratin linked to both CD8 and CD4 epitopes (AntpCD8-4) separated by a flanking native OVA sequence. 

We and others have utilized cell penetrating peptides including penetratin and HIV-Tat to shuttle proteins and peptides into the cytoplasm of antigen-presenting cells    ADDIN EN.CITE (14,21,26-32). AntpOVA was more efficiently internalized by in vitro grown DCs compared to OVA. At 4 M, 40-50% of DCs internalized AntpOVA within 5 minutes of incubation. There has been one published study thus far which the cell-penetrating peptide from HIV-I Tat protein (RKKRRQRRR) was chemically linked to OVA, successfully generating CTLs (33). When the HIV-I Tat peptide was linked to multiple CD8 and CD4 epitopes from OVA and furin-sensitive linker sequences were incorporated, potent CTL and Th responses were induced in vivo which showed striking prophylactic and therapeutic tumor protection against B16.OVA (25). Previously we have shown that immunizing mice with the Antennapedia membrane translocating sequence, penetratin, linked to the tumor-associated CTL peptide MUC1Kb, induced strong antigen-specific T cell responses in vivo and tumor protection (16). In the same study, mice immunized with penetratin linked to MUC1FP induced both CTL and Th anti-tumor responses in vivo (16). Furin-sensitive linker sequences have been shown in a previous study to be important for processing MHC class I restricted peptides for the HIV-Tat peptide linked to CD8+ and CD4+ T cell epitopes from OVA (25).

Functional in vitro studies showed that AntpOVA internalized and was processed and presented by MHC class I and II molecules to CD8+ and CD4+ T cells respectively. This was demonstrated using several methods – (i) stimulation of CD8+ specific B3Z T cell hybrids (Fig. 2) (ii) proliferation of T cells derived from OT-I mice and (iii) proliferation of T cells derived from OT-II mice. Furthermore, mice immunized with AntpOVA induced significant IFN- production after stimulation with CD4 and CD8 specific peptides in vivo. Splenocytes from mice immunized with OVA or CD8 and CD4 specific peptides without being linked to Antp did not induce IFN- responses to any stimulus (not shown). These results show linking Antp to a whole protein can induce both CD8+ and CD4+ antigen-specific responses in vitro and in vivo. This offers advantages over conventional peptide-based cancer vaccines particularly since multiple dominant and sub-dominant MHC class I and II restricted epitopes can be presented using whole protein as well as overcoming the tremendous polymorphism in the population. The majority of current peptide-based cancer vaccines in humans are individualized (restricted to one HLA-haplotype) and hence not suitable for the treatment of some patients.


Methods of generating Th effector cells, rather than just CTLs are now being incorporated into the design of peptide-based cancer vaccines. The multiepitope conjugate incorporating penetratin linked in tandem to CD8 and CD4 epitopes (AntpCD8-4) was able to stimulate B3Z T cells as well as OT-I and OT-II T cells in vitro; AntpCD8 stimulated B3Z T cells and OT-I T cells and AntpCD4 stimulated OT-II T cells in vitro. Furthermore, AntpCD8-4, AntpCD8 and AntpCD4 generated strong CD8+ and CD4+ antigen-specific IFN- T cells in vivo and inhibited OVA+ tumor growth (B16.OVA) in a prophylactic and therapeutic experimental tumor model. Immunization with AntpCD8-4, AntpCD8+AntpCD4 and AntpCD8 offered similar protection (delay in tumor growth); AntpOVA was slightly worse, where 2/6 tumors grew which appeared as early as 7 days. Additionally, the use of penetratin was potent despite not being used with any immune potentiators or adjuvants. These responses induced by AntpCD8-4 immunization are similar to the results reported by Lu and colleagues which showed that the multiepitope conjugate combining HIV-Tat with CD8 and CD4 epitopes generated all of the corresponding MHC class I-binding peptides which were recognized by CTLs only in the presence of furin-sensitive linker sequences (25). Additionally, HIV-Tat containing CTL epitopes were shown to localize in intracellular compartments and MHC class I-binding peptides were generated in a TAP-independent, aminopeptidase and endopeptidase furin-dependent manner (34). We have also shown similar MHC class I processing pathway results with AntpOVA however AntpCD8 is processed via a TAP-independent pathway with no further trimming required by aminopeptidases in the ER or by furin endopeptidases in the trans-Golgi (25). The AntpCD8-4 sequence did not include furin-sensitive sequences and was still able to process MHC class-I binding peptides. Although these findings were unlike what was reported by Lu and colleagues, these results did support our findings that Antp-peptides do not require the trans-Golgi to process and present MHC class I-binding peptides (17). These results proved interesting since a recent study showed that uptake of TAT-containing proteins and peptides was dependent on the properties of the cargo which in turn, could result in differences in MHC processing (35). As well, differences in uptake and processing mechanisms may be occurring due to the specific types of cells used in published studies. 

It appears that AntpCD8 is sufficient for inhibition of tumor growth without the need for immunization with AntpCD4, 7 days after the second immunization. Although co-immunization with AntpCD8 and AntpCD4 did not improve tumor protection 7 days after immunization compared to immunization with only AntpCD8, better IFN- responses and tumor suppression were observed 40 days after immunization. These results emphasize the importance of CD4+ T cell help for priming, sustaining and even augmenting tumor-specific CTL responses via direct mechanisms (cytotoxic effect on tumor itself) and indirect mechanisms (cytokine secretion) (36,37). A number of clinical studies are being performed to assess whether immunization with CD4+ T cell epitopes in combination with CTL peptide-based vaccines is more superior to CTL peptide-based vaccines alone (38). Interestingly, in our studies there was no difference in tumor protection observed between mice immunized with AntpCD8 or in combination with AntpCD8 and AntpCD4, 7 days after tumor challenge. Similar results were observed when mice immunized with TSA, a tumor specific antigen from the E7 protein of human papillomavirus 16, indicated no enhanced or suppressed CTL mediated tumor protection in the presence of antigen-specific CD4+ T cells (39). OVA-specific effector CTLs have also been shown to kill EG7 tumors in mice 7 days after immunization in the absence of CD4+ T cell help, yet this was not evident 14 days after immunization when effector OVA-specific CTL numbers were significantly lower (40). There are immunization regimes that show CD4 help affects CTL mediated tumor protection (41). What has become more apparent is the need for antigen-specific CD4+ T cell help to activate memory CTLs (mCTLs) (40). OVA-specific mCTLs generated with OVA-specific CD4+ help showed killing of EG7-OVA tumors, while those generated with KLH CD4+ T cell help did not (40). Subsequent studies showed that immunization with medium-sized peptides together with minimal CTL peptides provided sufficient CD4 help to induce mCTLs however this response was overridden after immunization with a CD4 T helper peptide (42). In long term experiments, mice immunized with AntpCD8 generated lower numbers of antigen-specific IFN- secreting T cells compared to mice immunized with AntpCD8-4 in tandem or AntpCD8 and AntpCD4 in combination. Likewise, in tumor challenge experiments, mice immunized with both AntpCD8 and AntpCD4 showed a more significant delay in B16.OVA tumor growth compared to mice immunized with AntpCD8 alone. This needs to be further evaluated in a tumor therapy model.






















































Fig. 1. Kinetics of uptake of AntpOVA by DCs. (A) DCs were incubated with OVA (-) or AntpOVA (-O-) for 5, 15, 30, 60 and 120 min at 4 M. DCs were incubated for 60 min with titrating concentrations of (B) OVA (-) and AntpOVA (-O-) or (C) AntpOVA (-O-) and PEPOVA (--) at 0.4-4 M. Cells were fixed, permeabilized and stained with a polyclonal rabbit anti-OVA followed by FITC-labelled F(ab’)2 anti-rabbit antibody and % positive cells analyzed by flow cytometry.

Fig. 2. Antp conjugates stimulate T cells in vitro. C57BL/6 DCs were stimulated with (A) AntpOVA or OVA, (B) AntpCD8-4, AntpCD4 or AntpCD8 for 24 h and added to B3Z T cells for 24 h. DCs alone and DCs pulsed with AntpCD4 were used as negative controls and DCs pulsed with AntpCD8 was used as an internal positive control. LacZ activity in total culture lysates from B3Z T cells was assayed via the LacZ substrate CPRG. The absorbance (560 nm) of culture wells was read after 4 h incubation at 37oC. Data is shown from triplicate wells (mean ± SD). Unpaired t-tests were performed and *p<0.05 indicates a significant difference and **p<0.001 indicates a very significant difference. Statistical analysis refers to comparison with the control in the same panel.

Fig. 3. Processing and presentation to MHC class I and II in vitro. DCs were pulsed with AntpOVA, OVA, AntpCD8, CD8, AntpCD4, CD4, AntpCD8-4 and PEPOVA at various concentrations for 24 h and added to purified (A-C) OT-I or (D-F) OT-II T cells and cultured for 6 days. Cells were harvested at each time point and uptake of [3H] was measured to assess T cell proliferation. DCs and OT-I T cells or OT-II T cells alone were used in both experiments as negative controls. Data presented as mean counts per minute (CPM) of [3H] thymidine uptake from quadruple wells ± SD. 

Fig. 4. CD8+ and CD4+ antigen-specific IFN- responses after immunization with Antp conjugates. C57BL/6 mice were immunized intradermally with (A) PBS alone (control) (B) AntpOVA, (C) AntpCD8-4, (D) AntpCD8+AntpCD4, (E) AntpCD4 and (F) AntpCD8. Immunizations were given twice, 14 days apart. 16 days post-immunization spleens were removed and IFN- responses assessed by ELISpot assay of reactivity to media alone (control), SIINFEKL peptide (CD8), OVA323-339 peptide (CD4) and ovalbumin protein (OVA) at 20 g/ml. Results are shown as spot forming (SFU) per 0.5 million cells. Data is shown from three replicate wells from three individual mice (mean ± SD). Unpaired t-tests were performed and *p<0.05 indicates a significant difference and **p<0.001 indicates a very significant difference. Statistical analysis refers to comparison with the control in the same panel.


Fig. 5. Protection against B16.OVA tumor challenge. Groups (n=6) of C57BL/6 mice received 2 intradermal injections with (A) PBS alone (control), (B) AntpOVA, (C) AntpCD8-4, (D) AntpCD8+AntpCD4, (E) AntpCD4 and (F) AntpCD8. 7 days later mice received a subcutaneous challenge of 1x106 B16.OVA tumor cells. Individual mouse curves are shown and tumor growth is only shown to day 11 as all mice were culled due to large tumor sizes. (G) Kaplan-Meier survival curves are shown.


Fig. 6. CD4+ T cell help enhances antigen-specific memory CD8+ T cell responses in vivo. C57BL/6 mice were immunized intradermally with (A) PBS alone (B) AntpOVA, (C) AntpCD8-4, (D) AntpCD8+AntpCD4, (E) AntpCD4 and (F) AntpCD8. Immunizations were given twice, 14 days apart. 40 days post-immunization spleens were removed and IFN- responses assessed by ELISpot assay of reactivity to media alone (control), SIINFEKL peptide (CD8), OVA323-339 peptide (CD4) and ovalbumin protein (OVA) at 20 g/ml. Results are shown as spot forming (SFU) per 0.5 million cells. Data is shown from triplicate wells from three individual mice (mean ± SD). Unpaired t-tests were performed and *p<0.05 indicates a significant difference and **p<0.001 indicates a very significant difference. Statistical analysis refers to comparison with the controls in the same panel.
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